Zosano Pharma Corporation (NASDAQ:ZSAN) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.05), Bloomberg Earnings reports.
Shares of Zosano Pharma Corporation (NASDAQ ZSAN) opened at $0.69 on Friday. Zosano Pharma Corporation has a one year low of $0.54 and a one year high of $3.54.
An institutional investor recently raised its position in Zosano Pharma Corporation stock. Vanguard Group Inc. increased its position in Zosano Pharma Corporation (NASDAQ:ZSAN) by 20.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,217,323 shares of the biotechnology company’s stock after purchasing an additional 209,251 shares during the period. Vanguard Group Inc. owned approximately 3.11% of Zosano Pharma Corporation worth $1,716,000 at the end of the most recent quarter. Institutional investors and hedge funds own 22.66% of the company’s stock.
Separately, ValuEngine raised Zosano Pharma Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.
TRADEMARK VIOLATION NOTICE: This piece was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://stocknewstimes.com/2017/11/11/zosano-pharma-corporation-zsan-releases-quarterly-earnings-results-misses-expectations-by-0-05-eps.html.
Zosano Pharma Corporation Company Profile
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Receive News & Ratings for Zosano Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.